- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00368368
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
November 1, 2016 updated by: Hoffmann-La Roche
An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.
This study will investigate the effect of renal impairment on the pharmacokinetics/pharmacodynamics of GK Activator (2) in patients with type 2 diabetes, and will evaluate the effect of renal function on the safety of the drug.
Patients will be assigned to treatment groups according to their renal function (normal, moderate renal impairment, or severe renal impairment).
After a 1 week washout period from current oral anti-diabetic treatment, all patients will receive a single oral dose of 100mg GK Activator (2), and blood and urine samples will be taken up to 96h post-dose.
The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bratislava, Slovakia, 833 01
-
-
-
-
California
-
Cypress, California, United States, 90630
-
-
Texas
-
Austin, Texas, United States, 78758
-
Dallas, Texas, United States, 75247
-
San Antonio, Texas, United States, 78229
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- adult patients, 18-75 years of age;
- type 2 diabetes, taken off current sulfonylureas and/or metformin therapy for >=1 week prior to dosing with GK Activator (2);
- normal renal function, or moderate or severe impairment.
Exclusion Criteria:
- type 1 diabetes;
- treatment with insulin or PPAR gamma agonist within 6 months of screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
100mg po
|
Experimental: 2
|
100mg po
|
Experimental: 3
|
100mg po
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Vital signs, adverse events, laboratory parameters.
Time Frame: Throughout study
|
Throughout study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC, Tmax, Cmax, T1/2, CL/F, CLR for GK Activator (2) and metabolite. Glucose Cmax and Cmin, and percentage decrease in glucose from baseline.
Time Frame: Throughout study.
|
Throughout study.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2006
Primary Completion (Actual)
August 1, 2007
Study Completion (Actual)
August 1, 2007
Study Registration Dates
First Submitted
August 22, 2006
First Submitted That Met QC Criteria
August 22, 2006
First Posted (Estimate)
August 24, 2006
Study Record Updates
Last Update Posted (Estimate)
November 2, 2016
Last Update Submitted That Met QC Criteria
November 1, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NP19470
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on GK Activator (2)
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Hungary, Poland, Bulgaria, Croatia, Mexico, Guatemala
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Estonia, Latvia, Mexico
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2Australia, Spain, Canada, United States, Germany, United Kingdom
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2Canada, United States, Hungary, Poland, Bulgaria, Croatia, Germany, Mexico, Guatemala, Australia
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States
-
Hoffmann-La RocheTerminatedDiabetes Mellitus, Type 2Germany, Slovakia
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States
-
Po-Lin Chen, MDGrape King Bio Ltd.CompletedLiver Cirrhosis | Portal HypertensionTaiwan
-
University College, LondonRecruiting
-
i-SENS, Inc.Avania; Rainier Clinical Research CenterTerminated